GlassScriptPhysician profile
Natalie Baker
NPI 1912402561
$1,833.69
in general payments reported to CMS, 2019-2025
27 companies · $540 in 2025
The $540 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.40 · 2022: $247 · 2023: $366 · 2024: $633 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $179.79 | 2021-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $133.90 | 2022-2025 | |
| Astellas Pharma US INC | $119.41 | 2024-2025 | Veozah |
| Abbvie INC. | $119.17 | 2022-2025 | |
| Lilly USA, LLC | $117.55 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $115.59 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $107.27 | 2023-2025 | Breztri, Airsupra |
| Antares Pharma, INC. | $101.20 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $94.00 | 2022 | |
| Glaxosmithkline, LLC. | $92.05 | 2024 | Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $91.90 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.49 | 2023-2024 | Jardiance, Tradjenta, Ofev |
| Pfizer INC. | $70.10 | 2024-2025 | |
| Rgh Enterprises LLC | $66.29 | 2025 | |
| Novartis Pharmaceuticals Corporation | $55.12 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $51.89 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $33.80 | 2023 | Camzyos |
| Halozyme INC | $32.88 | 2023 | |
| Sumitomo Pharma America, INC. | $24.88 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $24.12 | 2023 | Strensiq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.21 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $20.71 | 2024 | Xarelto |
| Lundbeck LLC | $17.82 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $15.58 | 2021 | |
| Ibsa Pharma INC. | $14.97 | 2023 | Tirosint, Licart |
| Tg Therapeutics, INC. | $13.08 | 2024 | |
| Seqirus USA INC | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.